| Literature DB >> 20981574 |
Marcos Schuch Azambuja1, Adroaldo Lunardelli, Robson Henrich Amaral, Fernanda Bordignon Nunes, Eduardo Caberlon, Vinicius Lorini da Costa, Márcio Vinícius Fagundes Donadio, Daniela Nunes Vitor, Alberto da Silva Melo Denizar, Silvio Cunha, Jarbas Rodrigues de Oliveira.
Abstract
RDV-8 [C(18)H(22)N(2)O(2)S (ethyl 1-butyl-6-methyl-2-phenyl-4-thioxo-1,4-dihydropyrimidine-5-carboxylate)] is derived from the 4-thioxopyrimidine, and presents important clinical effects. The present study explored the RDV-8 effects in the proliferation of human peripheral blood mononuclear cells (PBMCs), as well as in a pleurisy-induced rat model. PBMCs were directly plated in four different RDV-8 concentrations (0.0125, 0.025, 0.05 and 0.1 mg/mL). RDV-8 decreased cell proliferation and monocyte chemotactic protein 1 synthesis. The interleukin 1 levels and the cytotoxic effect were not significantly affected by RDV-8 treatment. In the carrageenan-induced pleurisy model, the RDV-8 (3 mg/kg) treatment induced a significant reduction in the exudate volume, in the polymorphonuclear leukocyte migration and in the pleural exudate NO levels. The results indicate that RDV-8 may have an immunomodulatory effect, as well as anti-inflammatory actions suggesting that it could represent a new strategy in the inflammatory response modulation.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20981574 DOI: 10.1007/s10787-010-0063-3
Source DB: PubMed Journal: Inflammopharmacology ISSN: 0925-4692 Impact factor: 4.473